graft versus host disease
Graft-versus-Host Disease Market

Graft-versus-Host Disease (GvHD) is an immune condition that occurs when immune cells after transplant procedures from the donor attack the recipient patient host’s tissues. It is caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes.

Graft-versus-Host Disease occurs when a particular type of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.

Graft-versus-Host Disease Epidemiology Segmentation in 7MM from 2018 to 2030

  • Total Hematopoietic Stem-Cell Transplantation (HSCT) Cases
  • Total Allogeneic Transplant Cases
  • Total GvHD Cases by Types (Acute and Chronic)
  • Total Incident Cases of aGvHD by Grading and Organ Involvement
  • Total Treated Patients of GvHD 
  • Mortality Adjusted GvHD Treated Patients

Graft-versus-Host Disease Epidemiology Insights Observed in 2020

  • The allogeneic Graft-versus-Host Disease (GvHD) cases were observed to be 24,049 in the 7MM. 
  • The allogeneic GvHD cases were observed to be 9,857 in the United States whereas 2,984 cases were observed in Germany in the year2020.
  • The cGvHD treated cases in first-line were accounted to be 3,278 in the United States in 2020. 
  • The GvHD cases by type were distinguished as 11,638 acute GVHD cases and 7,854 chronic GvHD cases.

Graft-versus-Host Disease Market Insights

The Graft-versus-Host Disease Market is expected to grow at a significant CAGR of 15.9% during the study period (2018-30).

Graft-versus-Host Disease Market Drivers

  • Increased participation in clinical trials along with novel strategies
  • The rise in the number of cases of allogeneic stem cell transplant

Graft-versus-Host Disease Market Barriers

  • Recognizing limitations of currently available aGvHD therapies
  • High cost of treatment 

Graft-versus-Host Disease Emerging Therapies

The emerging drugs in the Graft-versus-Host Disease market are 

  • Obnitix (MC0518)
  • MaaT013
  • Leukotac (Inolimomab)
  • SNDX-6532 (Axatilimab; GvHD B6352)
  • KD025 (Belumosudil)
  • Calquence (Acalabrutinib)
  • Tysabri (Natalizumab)
  • Efavaleukin Alfa (AMG 592)
  • Daurismo (Glasdegib)
  • AbGn-168H (Neihulizumab)
  • CSL 964 Alpha-1 antitrypsin (AAT)
  • Itacitinib
  • Entyvio (Vedolizumab; MLN0002)
  • MK-7110 (CD24Fc)
  • RGI-2001
  • Defitelio (Defibrotide)
  • Ninlaro (MLN 9708, MLN2238, Ixazomib)
  • Gazyva (Obinutuzumab)
  • Orencia (Abatacept)
  • T-Guard
  • SYN-004 (ribaxamase)
  • EQ001 (Itolizumab; Bmab600)
  • Pacritinib (Epjevy; ONX-0803)
  • Farydak (LBH-589, Panobinostat)
  • Benlysta (Belimumab) and several others

Graft-versus-Host Disease Key Players

The key companies in the Graft-versus-Host Disease market are 

  • Medac
  • MaaT Pharma
  • ElsaLys Biotech (Mediolanum Farmaceutici Spa)
  • Syndax Pharmaceutical
  • Kadmon Corporation
  • AstraZeneca
  • Biogen
  • Amgen
  • Pfizer
  • AltruBio
  • CSL Behring
  • Incyte Corporation
  • Takeda
  • OncoImmune
  • Regimmune Corporation
  • Jazz Pharmaceuticals
  • Millennium Pharmaceuticals
  • Roche-Genentech
  • Bristol-Myers Squibb
  • Xenikos
  • Synthetic Biologics
  • Equillium/Biocon
  • CTI BioPharma
  • Novartis
  • GlaxoSmithKline, 
  • Takeda Oncology
  • Merck (MSD), and several others